TNSN05014A1 - Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 - Google Patents

Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1

Info

Publication number
TNSN05014A1
TNSN05014A1 TNP2005000014A TNSN05014A TNSN05014A1 TN SN05014 A1 TNSN05014 A1 TN SN05014A1 TN P2005000014 A TNP2005000014 A TN P2005000014A TN SN05014 A TNSN05014 A TN SN05014A TN SN05014 A1 TNSN05014 A1 TN SN05014A1
Authority
TN
Tunisia
Prior art keywords
mip
alpha
binding
selective inhibitors
piperidine derivatives
Prior art date
Application number
TNP2005000014A
Other languages
English (en)
Inventor
Laura Cook Blumberg
Matthew Frank Brown
Matthew Merrill Hayward
Christopher Stanley Poss
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN05014A1 publication Critical patent/TNSN05014A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un composé de formule (I) : Dans laquelle A, B, C, R1, R2, R3, R4, R5, R6, Q, W, Y et Z répondent aux définitions précitées, utile comme inhibiteur puissant et sélectif de la liaison de MIP-1alpha (CCL3) à son récepteur CCR1 présent sur des cellules inflammatoires et immunomodulatrices (de préférence les leucocytes et lymphocytes).
TNP2005000014A 2002-07-18 2005-01-18 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1 TNSN05014A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39710802P 2002-07-18 2002-07-18
PCT/IB2003/002876 WO2004009550A1 (fr) 2002-07-18 2003-07-07 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison mip-1alpha a son recepteur ccr1

Publications (1)

Publication Number Publication Date
TNSN05014A1 true TNSN05014A1 (fr) 2007-05-14

Family

ID=30770997

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000014A TNSN05014A1 (fr) 2002-07-18 2005-01-18 Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1

Country Status (24)

Country Link
US (1) US20040063759A1 (fr)
EP (1) EP1534677A1 (fr)
JP (1) JP2005537279A (fr)
KR (1) KR20050021497A (fr)
CN (1) CN1668592A (fr)
AP (1) AP2005003200A0 (fr)
AR (1) AR040583A1 (fr)
AU (1) AU2003242941A1 (fr)
BR (1) BR0312946A (fr)
CA (1) CA2492651A1 (fr)
EC (1) ECSP055547A (fr)
HN (1) HN2003000222A (fr)
IL (1) IL166010A0 (fr)
IS (1) IS7614A (fr)
MA (1) MA27326A1 (fr)
MX (1) MXPA05000380A (fr)
OA (1) OA12885A (fr)
PA (1) PA8575901A1 (fr)
PE (1) PE20040666A1 (fr)
TN (1) TNSN05014A1 (fr)
TW (1) TW200402416A (fr)
UY (1) UY27897A1 (fr)
WO (1) WO2004009550A1 (fr)
ZA (1) ZA200500067B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399790B2 (en) 2001-02-28 2008-07-15 Konowalchuk Thomas W Virucidal compositions
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
JP4723242B2 (ja) 2002-06-12 2011-07-13 ケモセントリックス インコーポレーティッド 炎症および免疫障害治療用ｃｃｒ１アンタゴニストとして使用するための１−アリール−４−置換ピペラジン誘導体
WO2004009588A1 (fr) * 2002-07-18 2004-01-29 Pfizer Products Inc. Derives de piperidine bicycliques utilises comme antagonistes du recepteur de chimiokine ccr1
US8261062B2 (en) 2003-03-27 2012-09-04 Microsoft Corporation Non-cryptographic addressing
US7381738B2 (en) 2004-02-19 2008-06-03 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7479496B2 (en) 2004-02-19 2009-01-20 Bristol-Myers Squibb Company Substituted spiro azabicyclics as modulators of chemokine receptor activity
US7230022B2 (en) 2004-02-19 2007-06-12 Bristol-Myers Squibb Company Substituted fused bicyclic amines as modulators of chemokine receptor activity
US7288563B2 (en) 2004-02-19 2007-10-30 Bristol-Myers Squibb Company Substituted bicycloalkylamine derivatives as modulators of chemokine receptor activity
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2558211C (fr) 2004-03-03 2013-09-03 Chemocentryx, Inc. Heterocycles d'azote bicycliques et pontes
US7929689B2 (en) 2004-06-30 2011-04-19 Microsoft Corporation Call signs
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7620902B2 (en) 2005-04-20 2009-11-17 Microsoft Corporation Collaboration spaces
US7617281B2 (en) 2005-04-25 2009-11-10 Microsoft Corporation System and method for collaboration with serverless presence
US7660851B2 (en) 2005-07-06 2010-02-09 Microsoft Corporation Meetings near me
PT1907374E (pt) 2005-07-26 2012-11-05 Glaxo Group Ltd Derivados de benzilpiperazina úteis para o tratamento de doenças gastrointestinais
US7576106B2 (en) 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
US8086842B2 (en) 2006-04-21 2011-12-27 Microsoft Corporation Peer-to-peer contact exchange
US8069208B2 (en) 2006-04-21 2011-11-29 Microsoft Corporation Peer-to-peer buddy request and response
US8586571B2 (en) * 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
US20100168080A1 (en) * 2008-12-17 2010-07-01 Khamrai Uttam Novel compounds useful as cc chemokine receptor ligands
CN105829296A (zh) 2013-12-18 2016-08-03 巴斯夫欧洲公司 带有亚胺衍生的取代基的唑类化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (fr) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
CA2373942A1 (fr) * 1999-05-18 2000-11-23 Teijin Limited Remedes ou prophylactase contre les maladies associees a des chimiokines
AR028947A1 (es) * 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
CN100413860C (zh) * 2001-07-24 2008-08-27 匈牙利吉瑞大药厂 作为nmda受体拮抗剂的哌啶衍生物

Also Published As

Publication number Publication date
AP2005003200A0 (en) 2005-03-31
MXPA05000380A (es) 2005-03-31
AU2003242941A1 (en) 2004-02-09
OA12885A (en) 2006-09-15
KR20050021497A (ko) 2005-03-07
CA2492651A1 (fr) 2004-01-29
EP1534677A1 (fr) 2005-06-01
BR0312946A (pt) 2005-07-12
PA8575901A1 (es) 2004-07-20
UY27897A1 (es) 2004-02-27
US20040063759A1 (en) 2004-04-01
WO2004009550A1 (fr) 2004-01-29
ZA200500067B (en) 2005-11-02
HN2003000222A (es) 2004-11-23
IS7614A (is) 2004-12-23
MA27326A1 (fr) 2005-05-02
IL166010A0 (en) 2006-01-15
CN1668592A (zh) 2005-09-14
JP2005537279A (ja) 2005-12-08
PE20040666A1 (es) 2004-09-25
ECSP055547A (es) 2005-03-10
TW200402416A (en) 2004-02-16
AR040583A1 (es) 2005-04-13

Similar Documents

Publication Publication Date Title
TNSN05014A1 (fr) Derives de piperidine et leur utilisation comme inhibiteurs selectifs de la liaison de mip-1 alpha a son recepteur ccr1
TNSN05013A1 (fr) Derives de piperidine bicycliques servant d'antagonistes du recepteur de chimiokine ccr1
NO20061978L (no) Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon
MA28432B1 (fr) Antagonistes du recepteur de la chimiokine
CO5261539A1 (es) Compuestos farmaceuticamente activos
GEP20074152B (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
TR199701356A2 (xx) L�kozit adhasyonu inhibit�rleri ve VLA-4-antagonistleri olarak heterosiklenler.
ES2160408T3 (es) Trifluorfenil-triazolpirimidinas fungicidas.
HUP0500610A2 (hu) Indazol-, benzotiazol- és benzoizotiazol-származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása
SE0302486D0 (sv) Novel compounds
DK0734381T3 (da) Morpholin- og thiomorpholintachykininreceptorantagonister
NO20063380L (no) Triazolderivater som vasopressinantagonister
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
DE602005012634D1 (en) Arylsulfonylnaphthalinderivate als 5ht2a-antagonisten
RU2008127257A (ru) Тризамещенные производные хиназолинона в качестве ваниллоидных антагонистов
ATE338461T1 (de) Pyrazolpyrimidinfungizide
ECSP055912A (es) Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor de difosfato de adenosina en plaquetas
SE0302324D0 (sv) Novel compounds
NO20052866L (no) Imidazokinolinderivater som adenosin A3 reseptorligander
SE0302323D0 (sv) Novel compounds
MEP19108A (en) Aminoquinoline derivatives and their use as adenosine a3 ligands
BR0311333A (pt) ésteres na posição 20 de camptotecinas
ATE246174T1 (de) Tosylprolin-derivate als thymidylat-synthase inhibitoren
EA200101096A1 (ru) Применение производных мадурафталазина в качестве ингибиторов провоспалительных цитокинов
CO5210926A1 (es) Mezclas fungicidas